Pharmacological potential of exercise and RAS vasoactive peptides for prevention of diseases

Current Protein and Peptide Science

Volumn 14, Issue 6, 2013, Pages 459-471

  Petriz, Bernardo de Assis ^a   de Almeida, Jeeser Alves ^a   Migliolo, Ludovico ^a   Franco, Octávio Luíz ^a  

^a UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

Author keywords

Angiotensin (1 7); Exercise; Hypertension; Pharmacology; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN [1-5]; ANGIOTENSIN [1-9]; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN III; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; ANGIOTENSINOGEN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPERTENSIVE AGENT; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; MAS RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PEPTIDE HORMONE; UNCLASSIFIED DRUG; UROTENSIN II; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE PEPTIDE; ZINC FINGER PROTEIN; ANGIOTENSIN DERIVATIVE;

EXERCISE; HUMAN; HYPERTENSION; NONHUMAN; POST EXERCISE HYPOTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SWIMMING; VASODILATATION; ANIMAL; CHEMICAL STRUCTURE; DISEASES; DRUG EFFECTS; PHYSIOLOGY; PREVENTIVE MEDICINE;

ANGIOTENSINS; ANIMALS; DISEASE; EXERCISE; HUMANS; MODELS, MOLECULAR; PREVENTIVE MEDICINE; RENIN-ANGIOTENSIN SYSTEM;

EID: 84888242009     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/13892037113149990063     Document Type: Review

References (151)

1. Giles, T. D.; Materson, B. J.; Cohn, J. N.; Kostis, J. B., Definition and classification of hypertension: an update. J. Clin. Hypertens. (Greenwich), 2009, 11(11), 611-614.
2. Carretero, O. A.; Oparil, S. Essential hypertension. Part I: definition and etiology. Circulation, 2000, 101(3), 329-335.
3. Leone, A., Modifying cardiovascular risk factors: epidemiology and characteristics of hypertension-related disorders. Curr. Pharm. Des., 2011, 17(28), 2948-2954.
4. Unger, T.; Paulis, L.; Sica, D. A. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur. Heart J., 2011, 32(22), 2739-2747.
5. Ferreira, A. J.; Murca, T. M.; Fraga-Silva, R. A.; Castro, C. H.; Raizada, M. K.; Santos, R. A. New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int. J. Hypertens., 2012, 147825.
6. Paul, M.; Poyan Mehr, A.; Kreutz, R., Physiology of local reninangiotensin systems. Physiol Rev., 2006, 86(3), 747-803.
7. Iwai, M.; Horiuchi, M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens. Res., 2009, 32(7), 533-536.
8. Moilanen, A. M.; Rysa, J.; Serpi, R.; Mustonen, E.; Szabo, Z.; Aro, J.; Napankangas, J.; Tenhunen, O.; Sutinen, M.; Salo, T.; Ruskoaho, H. (Pro)renin receptor triggers distinct angiotensin IIindependent extracellular matrix remodeling and deterioration of cardiac function. PLoS One, 2012, 7(7), e41404.
9. Santos, R. A.; Castro, C. H.; Gava, E.; Pinheiro, S. V.; Almeida, A. P.; Paula, R. D.; Cruz, J. S.; Ramos, A. S.; Rosa, K. T.; Irigoyen, M. C.; Bader, M.; Alenina, N.; Kitten, G. T.; Ferreira, A. J., Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension, 2006, 47(5), 996-1002.
10. Santos, R. A.; Simoes e Silva, A. C.; Maric, C.; Silva, D. M.; Machado, R. P.; de Buhr, I.; Heringer-Walther, S.; Pinheiro, S. V.; Lopes, M. T.; Bader, M.; Mendes, E. P.; Lemos, V. S.; Campagnole-Santos, M. J.; Schultheiss, H. P.; Speth, R.; Walther, T. Angiotensin-(1-7) is an endogenous ligand for the G proteincoupled receptor Mas. Proc. Natl. Acad. Sci. USA, 2003, 100(14), 8258-8263.
11. Guimaraes, G. G.; Santos, S. H.; Oliveira, M. L.; Pimenta-Velloso, E. P.; Motta, D. F.; Martins, A. S.; Alenina, N.; Bader, M.; Santos, R. A.; Campagnole-Santos, M. J. Exercise induces reninangiotensin system unbalance and high collagen expression in the heart of Mas-deficient mice. Peptides, 2012, 38(1), 54-61.
12. Agarwal, D.; Welsch, M. A.; Keller, J. N.; Francis, J. Chronic exercise modulates RAS components and improves balance between pro-and anti-inflammatory cytokines in the brain of SHR. Basic Res. Cardiol., 2011, 106(6), 1069-1085.
13. Gielen, S.; Schuler, G.; Adams, V. Cardiovascular effects of exercise training: molecular mechanisms. Circulation, 2010, 122(12), 1221-1238.
14. Shah, A.; Oh, Y. B.; Lee, S. H.; Lim, J. M.; Kim, S. H. Angiotensin-(1-7) attenuates hypertension in exercise-trained renal hypertensive rats. Am. J. Physiol. Heart Circ. Physiol., 2012, 302(11), H2372-H2380.
15. Peart, W. S. Renin-angiotensin system. N. Engl. J. Med., 1975, 292(6), 302-306.
16. Basso, N.; Terragno, N. A. History about the discovery of the renin-angiotensin system. Hypertension, 2001, 38(6), 1246-1249.
17. Tigerstedt, R.; Bergman, P.G. Niere und Kreislauf. Skand Arch. Physiol., 1898, 8, 223-271.
18. Celerier, J.; Schmid, G.; Le Caer, J. P.; Gimenez-Roqueplo, A. P.; Bur, D.; Friedlein, A.; Langen, H.; Corvol, P.; Jeunemaitre, X. Characterization of a human angiotensinogen cleaved in its reactive center loop by a proteolytic activity from Chinese hamster ovary cells. J. Biol. Chem., 2000, 275(14), 10648-10654.
19. Pratt, R. E.; Flynn, J. A.; Hobart, P. M.; Paul, M.; Dzau, V. J. Different secretory pathways of renin from mouse cells transfected with the human renin gene. J. Biol. Chem., 1988, 263(7), 3137-3141.
20. Morris, B. J. Renin: from 'pro' to promoter. Bioessays, 2003, 25(5), 520-527.
21. Shiratori, Y.; Nakagawa, S.; Hori, H.; Murakami, K.; Umeyama, H. Protein modeling of human prorenin using the molecular dynamics method. J. Mol. Graph., 1990, 8(3), 163-167, 150.
22. D'Elia, J. A.; Bayliss, G.; Roshan, B.; Maski, M.; Gleason, R. E.; Weinrauch, L. A. Diabetic microvascular complications: possible targets for improved macrovascular outcomes. Int. J. Nephrol. Renovasc. Dis., 2011, 4, 1-15.
23. Schalekamp, M. A. Renin-angiotensin system components and endothelial proteins as markers of diabetic microvascular disease. Clin. Investig., 1993, 71(5 Suppl), S3-S6.
24. Rafiq, K.; Mori, H.; Masaki, T.; Nishiyama, A. (Pro)renin receptor and insulin resistance: Possible roles of angiotensin II-dependent and-independent pathways. Mol. Cell Endocrinol., 2012.
25. Satofuka, S.; Ichihara, A.; Nagai, N.; Noda, K.; Ozawa, Y.; Fukamizu, A.; Tsubota, K.; Itoh, H.; Oike, Y.; Ishida, S. (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes, 2009, 58(7), 1625-1633.
26. Nguyen, G.; Delarue, F.; Burckle, C.; Bouzhir, L.; Giller, T.; Sraer, J. D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest., 2002, 109(11), 1417-1427.
27. Funke-Kaiser, H.; Zollmann, F. S.; Schefe, J. H.; Unger, T. Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage. Hypertens. Res., 2010, 33(2): 98-104.
28. Ichihara, A.; Sakoda, M.; Kurauchi-Mito, A.; Narita, T.; Kinouchi, K.; Itoh, H. Drug discovery for overcoming chronic kidney disease (CKD): new therapy for CKD by a (pro)renin-receptor-blocking decoy peptide. J. Pharmacol. Sci., 2009, 109(1), 20-23.
29. Ichihara, A.; Hayashi, M.; Kaneshiro, Y.; Suzuki, F.; Nakagawa, T.; Tada, Y.; Koura, Y.; Nishiyama, A.; Okada, H.; Uddin, M. N.; Nabi, A. H.; Ishida, Y.; Inagami, T.; Saruta, T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J. Clin. Invest., 2004, 114(8), 1128-1135.
30. Susic, D.; Zhou, X.; Frohlich, E. D.; Lippton, H.; Knight, M. Cardiovascular effects of prorenin blockade in genetically spontaneously hypertensive rats on normal and high-salt diet. Am. J. Physiol. Heart Circ. Physiol., 2008, 295(3), H1117-H1121.
31. Masuyer, G.; Schwager, S. L.; Sturrock, E. D.; Isaac, R. E.; Acharya, K. R. Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides. Sci. Rep., 2012, 2, 717.
32. Matsuda, H.; Hayashi, K.; Wakino, S.; Kubota, E.; Honda, M.; Tokuyama, H.; Takamatsu, I.; Tatematsu, S.; Saruta, T. Role of endothelium-derived hyperpolarizing factor in ACE inhibitorinduced renal vasodilation in vivo. Hypertension, 2004, 43(3), 603-609.
33. Imig, J. D., ACE Inhibition and Bradykinin-Mediated Renal Vascular Responses: EDHF Involvement. Hypertension, 2004, 43(3), 533-535.
34. Ikeda, M.; Sasaguri, M.; Maruta, H.; Arakawa, K. Formation of angiotensin II by tonin-inhibitor complex. Hypertension, 1988, 11(1), 63-70.
35. Jackman, H. L.; Massad, M. G.; Sekosan, M.; Tan, F.; Brovkovych, V.; Marcic, B. M.; Erdos, E. G. Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension, 2002, 39(5), 976-981.
36. Miller, J. J.; Changaris, D. G.; Levy, R. S. Conversion of angiotensin I to angiotensin II by cathepsin A isoenzymes of porcine kidney. Biochem. Biophys. Res. Commun., 1988, 154(3), 1122-1129.
37. Ahmad, S.; Simmons, T.; Varagic, J.; Moniwa, N.; Chappell, M. C.; Ferrario, C. M. Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue. PLoS One, 2011, 6(12), e28501.
38. Garabelli, P. J.; Modrall, J. G.; Penninger, J. M.; Ferrario, C. M.; Chappell, M. C. Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. Exp. Physiol., 2008, 93(5), 613-621.
39. Arakawa, K.; Urata, H. Hypothesis regarding the pathophysiological role of alternative pathways of angiotensin II formation in atherosclerosis. Hypertension, 2000, 36(4), 638-641.
40. Wright, J. W.; Mizutani, S.; Harding, J. W. Focus on Brain Angiotensin III and Aminopeptidase A in the Control of Hypertension. Int. J. Hypertens., 2012, 2012, 124758.
41. Higuchi, S.; Ohtsu, H.; Suzuki, H.; Shirai, H.; Frank, G. D.; Eguchi, S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin. Sci. (Lond), 2007, 112(8), 417-428.
42. McConnaughey, M. M.; McConnaughey, J. S.; Ingenito, A. J. Practical considerations of the pharmacology of angiotensin receptor blockers. J. Clin. Pharmacol., 1999, 39(6), 547-559.
43. Flores-Munoz, M.; Work, L. M.; Douglas, K.; Denby, L.; Dominiczak, A. F.; Graham, D.; Nicklin, S. A. Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension, 2012, 59(2), 300-307.
44. Ocaranza, M. P.; Lavandero, S.; Jalil, J. E.; Moya, J.; Pinto, M.; Novoa, U.; Apablaza, F.; Gonzalez, L.; Hernandez, C.; Varas, M.; Lopez, R.; Godoy, I.; Verdejo, H.; Chiong, M. Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. J. Hypertens., 2010, 28(5), 1054-1064.
45. Miura, S.; Matsuo, Y.; Kiya, Y.; Karnik, S. S.; Saku, K. Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors. Biochem. Biophys. Res. Commun., 2010, 391(1), 85-90.
46. Funke-Kaiser, H.; Reinemund, J.; Steckelings, U. M.; Unger, T. Adapter proteins and promoter regulation of the angiotensin AT2 receptor--implications for cardiac pathophysiology. J. Renin. Angiotensin Aldosterone Syst., 2010, 11(1), 7-17.
47. Seyedi, N.; Xu, X.; Nasjletti, A.; Hintze, T. H. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension, 1995, 26(1), 164-170.
48. Steckelings, U. M.; Rompe, F.; Kaschina, E.; Namsolleck, P.; Grzesiak, A.; Funke-Kaiser, H.; Bader, M.; Unger, T. The past, present and future of angiotensin II type 2 receptor stimulation. J. Renin. Angiotensin Aldosterone Syst., 2010, 11(1), 67-73.
49. Kaschina, E.; Grzesiak, A.; Li, J.; Foryst-Ludwig, A.; Timm, M.; Rompe, F.; Sommerfeld, M.; Kemnitz, U. R.; Curato, C.; Namsolleck, P.; Tschope, C.; Hallberg, A.; Alterman, M.; Hucko, T.; Paetsch, I.; Dietrich, T.; Schnackenburg, B.; Graf, K.; Dahlof, B.; Kintscher, U.; Unger, T.; Steckelings, U. M. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation, 2008, 118(24), 2523-2532.
50. Williams, J. S.; Williams, G. H. 50th anniversary of aldosterone. J. Clin. Endocrinol. Metab., 2003, 88(6), 2364-2372.
51. Kushibiki, M.; Yamada, M.; Oikawa, K.; Tomita, H.; Osanai, T.; Okumura, K. Aldosterone causes vasoconstriction in coronary arterioles of rats via angiotensin II type-1 receptor: influence of hypertension. Eur. J. Pharmacol., 2007, 572(2-3), 182-188.
52. Yamada, M.; Kushibiki, M.; Osanai, T.; Tomita, H.; Okumura, K. Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovasc. Res., 2008, 79(1), 169-178.
53. Robert, V.; Heymes, C.; Silvestre, J. S.; Sabri, A.; Swynghedauw, B.; Delcayre, C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension, 1999, 33(4), 981-986.
54. Rocha, R.; Rudolph, A. E.; Frierdich, G. E.; Nachowiak, D. A.; Kekec, B. K.; Blomme, E. A.; McMahon, E. G.; Delyani, J. A. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol., 2002, 283(5), H1802-H1810.
55. Brilla, C. G.; Pick, R.; Tan, L. B.; Janicki, J. S.; Weber, K. T. Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res., 1990, 67(6), 1355-1364.
56. Young, M. J.; Funder, J. W., Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. J. Hypertens., 2002, 20(8), 1465-1468.
57. Reid, I. A. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am. J. Physiol. Endocrinol. Metab., 1992, 262, E763-E778.
58. Busatto, V. C.; Cunha, V.; Cicilini, M. A.; Mill, J. G. Differential effects of isoproterenol on the activity of angiotensin-converting enzyme in the rat heart and aorta. Braz. J. Med. Biol. Res., 1999, 32(3), 355-360.
59. Spinale, F. G.; Holzgrefe, H. H.; Mukherjee, R.; Hird, R. B.; Walker, J. D.; Arnim-Barker, A.; Powell, J. R.; Koster, W. H., Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function. Circulation, 1995, 92(3), 562-578.
60. Santos, R. A.; Campagnole-Santos, M. J.; Andrade, S. P. Angiotensin-(1-7): an update. Regul. Pept., 2000, 91(1-3), 45-62.
61. Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; Stagliano, N.; Donovan, M.; Woolf, B.; Robison, K.; Jeyaseelan, R.; Breitbart, R. E.; Acton, S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res., 2000, 87(5), E1-E9.
62. Tipnis, S. R.; Hooper, N. M.; Hyde, R.; Karran, E.; Christie, G.; Turner, A. J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem., 2000, 275(43), 33238-33243.
63. Vickers, C.; Hales, P.; Kaushik, V.; Dick, L.; Gavin, J.; Tang, J.; Godbout, K.; Parsons, T.; Baronas, E.; Hsieh, F.; Acton, S.; Patane, M.; Nichols, A.; Tummino, P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem., 2002, 277(17), 14838-14843.
64. Kassiri, Z.; Zhong, J.; Guo, D.; Basu, R.; Wang, X.; Liu, P. P.; Scholey, J. W.; Penninger, J. M.; Oudit, G. Y. Loss of angiotensinconverting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ. Heart Fail., 2009, 2(5), 446-455.
65. Grobe, J. L.; Der Sarkissian, S.; Stewart, J. M.; Meszaros, J. G.; Raizada, M. K.; Katovich, M. J. ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin. Sci. (Lond), 2007, 113(8), 357-364.
66. Floras, J. S. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J. Am. Coll. Cardiol., 1993, 22(4 Suppl A), 72A-84A.
67. Francis, G. S. Neurohumoral mechanisms involved in congestive heart failure. Am. J. Cardiol., 1985, 55(2), 15A-21A.
68. McKinley, M. J.; Albiston, A. L.; Allen, A. M.; Mathai, M. L.; May, C. N.; McAllen, R. M.; Oldfield, B. J.; Mendelsohn, F. A.; Chai, S. Y. The brain renin-angiotensin system: location and physiological roles. Int. J. Biochem. Cell Biol., 2003, 35(6), 901-918.
69. Doobay, M. F.; Talman, L. S.; Obr, T. D.; Tian, X.; Davisson, R. L.; Lazartigues, E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 292(1), R373-R381.
70. Feng, Y.; Yue, X.; Xia, H.; Bindom, S. M.; Hickman, P. J.; Filipeanu, C. M.; Wu, G.; Lazartigues, E. Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ. Res., 2008, 102(6), 729-736.
71. Ferrario, C. M.; Chappell, M. C.; Dean, R. H.; Iyer, S. N. Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis. J. Am. Soc. Nephrol., 1998, 9(9), 1716-1722.
72. Le Tran, Y.; Forster, C. Angiotensin-(1-7) and the rat aorta: modulation by the endothelium. J. Cardiovasc. Pharmacol., 1997, 30(5), 676-682.
73. Ren, Y.; Garvin, J. L.; Carretero, O. A. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension, 2002, 39(3), 799-802.
74. Sampaio, W. O.; Nascimento, A. A.; Santos, R. A. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am. J. Physiol. Heart Circ. Physiol., 2003, 284(6), H1985-H1994.
75. Campbell, D. J.; Zeitz, C. J.; Esler, M. D.; Horowitz, J. D., Evidence against a major role for angiotensin converting enzymerelated carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. J. Hypertens., 2004, 22(10), 1971-1976.
76. Rice, G. I.; Thomas, D. A.; Grant, P. J.; Turner, A. J.; Hooper, N. M. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem. J., 2004, 383(Pt 1), 45-51.
77. Jackson, T. R.; Blair, L. A.; Marshall, J.; Goedert, M.; Hanley, M. R. The mas oncogene encodes an angiotensin receptor. Nature, 1988, 335(6189), 437-440.
78. Kostenis, E.; Milligan, G.; Christopoulos, A.; Sanchez-Ferrer, C. F.; Heringer-Walther, S.; Sexton, P. M.; Gembardt, F.; Kellett, E.; Martini, L.; Vanderheyden, P.; Schultheiss, H. P.; Walther, T. Gprotein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation, 2005, 111(14), 1806-1813.
79. Averill, D. B.; Ishiyama, Y.; Chappell, M. C.; Ferrario, C. M., Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation, 2003, 108(17), 2141-2146.
80. Mercure, C.; Yogi, A.; Callera, G. E.; Aranha, A. B.; Bader, M.; Ferreira, A. J.; Santos, R. A.; Walther, T.; Touyz, R. M.; Reudelhuber, T. L. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ. Res., 2008, 103(11), 1319-1326.
81. Almeida, A. P.; Frabregas, B. C.; Madureira, M. M.; Santos, R. J.; Campagnole-Santos, M. J.; Santos, R. A. Angiotensin-(1-7) potentiates the coronary vasodilatatory effect of bradykinin in the isolated rat heart. Braz. J. Med. Biol. Res., 2000, 33(6), 709-713.
82. Crackower, M. A.; Sarao, R.; Oudit, G. Y.; Yagil, C.; Kozieradzki, I.; Scanga, S. E.; Oliveira-dos-Santos, A. J.; da Costa, J.; Zhang, L.; Pei, Y.; Scholey, J.; Ferrario, C. M.; Manoukian, A. S.; Chappell, M. C.; Backx, P. H.; Yagil, Y.; Penninger, J. M. Angiotensinconverting enzyme 2 is an essential regulator of heart function. Nature, 2002, 417(6891), 822-828.
83. Ishiyama, Y.; Gallagher, P. E.; Averill, D. B.; Tallant, E. A.; Brosnihan, K. B.; Ferrario, C. M. Upregulation of angiotensinconverting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension, 2004, 43(5), 970-976.
84. Huentelman, M. J.; Grobe, J. L.; Vazquez, J.; Stewart, J. M.; Mecca, A. P.; Katovich, M. J.; Ferrario, C. M.; Raizada, M. K. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp. Physiol., 2005, 90(5), 783-790.
85. Diez-Freire, C.; Vazquez, J.; Correa de Adjounian, M. F.; Ferrari, M. F.; Yuan, L.; Silver, X.; Torres, R.; Raizada, M. K. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol. Genomics, 2006, 27(1), 12-19.
86. Raizada, M. K.; Ferreira, A. J. ACE2: a new target for cardiovascular disease therapeutics. J. Cardiovasc. Pharmacol., 2007., 50(2), 112-119.
87. Ueda, S.; Masumori-Maemoto, S.; Ashino, K.; Nagahara, T.; Gotoh, E.; Umemura, S.; Ishii, M. Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension, 2000, 35(4), 998-1001.
88. Benter, I. F.; Yousif, M. H.; Anim, J. T.; Cojocel, C.; Diz, D. I. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am. J. Physiol. Heart Circ. Physiol., 2006, 290(2), H684-H691.
89. Loot, A. E.; Roks, A. J.; Henning, R. H.; Tio, R. A.; Suurmeijer, A. J.; Boomsma, F.; van Gilst, W. H. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation, 2002, 105(13), 1548-1550.
90. WHO, Global recommendations on physical activity for health. 2010, Geneva, Switzerland: WHO Press.
91. Petriz, B. A.; Cunha, V. N.; Villeth, G. R.; Mehta, A.; Rocha, L. A.; Silva, O. N.; Almeida, J. A.; Morais, P. K.; Simoes, H. G.; Franco, O. L. Effects of acute exercise over heart proteome from monogenic obese (ob/ob) mice. J. Cell Physiol., 2012.
92. Rocha, L. A.; Petriz, B.; Borges, D. H.; Oliveira, R. J.; Andrade, R. V.; Domondt, G.; Pereira, R. W.; Franco, O. L. High molecular mass proteomics analyses of left ventricle from rats subjected to differential swimming training. BMC Physiol., 2012, 12(1), 11.
93. Kolwicz, S. C.; MacDonnell, S. M.; Renna, B. F.; Reger, P. O.; Seqqat, R.; Rafiq, K.; Kendrick, Z. V.; Houser, S. R.; Sabri, A.; Libonati, J. R. Left ventricular remodeling with exercise in hypertension. Am. J. Physiol. Heart Circ. Physiol., 2009, 297(4), H1361-H1368.
94. Turner, M. J.; Spina, R. J.; Kohrt, W. M.; Ehsani, A. A., Effect of endurance exercise training on left ventricular size and remodeling in older adults with hypertension. J. Gerontol. A. Biol. Sci. Med. Sci., 2000, 55(4), M245-M251.
95. Palatini, P. Cardiovascular effects of exercise in young hypertensives. Int. J. Sports Med., 2012, 33(9), 683-690.
96. Ford, E. S. Trends in Mortality From All Causes and Cardiovascular Disease Among Hypertensive and Nonhypertensive Adults in the United States. Circularion, 2011, 123(16).
97. Halliwill, J. R. Mechanisms and clinical implications of postexercise hypotension in humans. Exerc. Sport Sci. Rev., 2001, 29(2), 65-70.
98. MacDonald, J. R. Potential causes, mechanisms, and implications of post exercise hypotension. J. Hum. Hypertens., 2002, 16(4), 225-236.
99. Almeida, J.A.; Petriz, B.A.; Gomes, C.P.C.; Pereira, R.W.; Franco, O.L. Assessment of maximal lactate steady state during treadmill exercise in SHR. BMC Res. Notes, 2012, 5, (661).
100. Moraes, M. R.; Bacurau, R. F.; Casarini, D. E.; Jara, Z. P.; Ronchi, F. A.; Almeida, S. S.; Higa, E. M.; Pudo, M. A.; Rosa, T. S.; Haro, A. S.; Barros, C. C.; Pesquero, J. B.; Wurtele, M.; Araujo, R. C. Chronic conventional resistance exercise reduces blood pressure in stage 1 hypertensive men. J. Strength Cond. Res., 2012, 26(4), 1122-1129.
101. Morais, P. K.; Campbell, C. S.; Sales, M. M.; Motta, D. F.; Moreira, S. R.; Cunha, V. N.; Benford, R. E.; Simoes, H. G. Acute resistance exercise is more effective than aerobic exercise for 24h blood pressure control in type 2 diabetics. Diabetes Metab., 2011, 37(2), 112-117.
102. Scher, L. M.; Ferriolli, E.; Moriguti, J. C.; Scher, R.; Lima, N. K. The effect of different volumes of acute resistance exercise on elderly individuals with treated hypertension. J. Strength Cond. Res., 2011, 25(4), 1016-1023.
103. Lee, S. K.; Kim, C. S.; Kim, H. S.; Cho, E. J.; Joo, H. K.; Lee, J. Y.; Lee, E. J.; Park, J. B.; Jeon, B. H. Endothelial nitric oxide synthase activation contributes to post-exercise hypotension in spontaneously hypertensive rats. Biochem. Biophys. Res. Commun., 2009, 382(4), 711-714.
104. Le, V. V.; Mitiku, T.; Sungar, G.; Myers, J.; Froelicher, V. The blood pressure response to dynamic exercise testing: a systematic review. Prog. Cardiovasc. Dis., 2008, 51(2), 135-160.
105. Rogers, M. W.; Probst, M. M.; Gruber, J. J.; Berger, R.; Boone, J. B., Jr. Differential effects of exercise training intensity on blood pressure and cardiovascular responses to stress in borderline hypertensive humans. J. Hypertens., 1996, 14(11), 1369-1375.
106. Jones, H.; George, K.; Edwards, B.; Atkinson, G. Is the magnitude of acute post-exercise hypotension mediated by exercise intensity or total work done? Eur. J. Appl. Physiol., 2007, 102(1), 33-40.
107. Sebai, M.; Lu, S.; Xiang, L.; Hester, R. L. Improved functional vasodilation in obese Zucker rats following exercise training. Am. J. Physiol. Heart Circ. Physiol., 2011, 301(3), H1090-H1096.
108. Forstermann, U.; Sessa, W. C. Nitric oxide synthases: regulation and function. Eur. Heart J., 2012, 33(7), 829-837, 837a-837d.
109. Begum, N.; Sandu, O. A.; Ito, M.; Lohmann, S. M.; Smolenski, A. Active Rho kinase (ROK-alpha) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells. J. Biol. Chem., 2002, 277(8), 6214-6222.
110. Munzel, T.; Feil, R.; Mulsch, A.; Lohmann, S. M.; Hofmann, F.; Walter, U. Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphate-dependent protein kinase [corrected]. Circulation, 2003, 108(18), 2172-2183.
111. Tschakovsky, M. E.; Joyner, M. J. Nitric oxide and muscle blood flow in exercise. Appl. Physiol. Nutr. Metab., 2008, 33(1), 151-161.
112. Maiorana, A.; O'Driscoll, G.; Taylor, R.; Green, D. Exercise and the nitric oxide vasodilator system. Sports Med., 2003, 33(14), 1013-1035.
113. Hirai, D. M.; Copp, S. W.; Ferguson, S. K.; Holdsworth, C. T.; McCullough, D. J.; Behnke, B. J.; Musch, T. I.; Poole, D. C. Exercise training and muscle microvascular oxygenation: functional role of nitric oxide. J. Appl. Physiol., 2012, 113(4), 557-565.
114. McConell, G. K.; Rattigan, S.; Lee-Young, R. S.; Wadley, G. D.; Merry, T. L. Skeletal muscle nitric oxide signaling and exercise: a focus on glucose metabolism. Am. J. Physiol. Endocrinol. Metab., 2012, 303(3), E301-E307.
115. Levine, A. B.; Punihaole, D.; Levine, T. B. Characterization of the role of nitric oxide and its clinical applications. Cardiology, 2012, 122(1), 55-68.
116. Silva, D. M.; Gomes-Filho, A.; Olivon, V. C.; Santos, T. M.; Becker, L. K.; Santos, R. A.; Lemos, V. S. Swimming training improves the vasodilator effect of angiotensin-(1-7) in the aorta of spontaneously hypertensive rat. J. Appl. Physiol., 2011, 111(5), 1272-1277.
117. Wang, Y.; Wang, S.; Wier, W. G.; Zhang, Q.; Jiang, H.; Li, Q.; Chen, S.; Tian, Z.; Li, Y.; Yu, X.; Zhao, M.; Liu, J.; Yang, J.; Zhang, J.; Zang, W. Exercise improves the dilatation function of mesenteric arteries in postmyocardial infarction rats via a PI3K/Akt/eNOS pathway-mediated mechanism. Am. J. Physiol. Heart Circ. Physiol., 2010, 299(6), H2097-H20106.
118. Allen, A. M.; Zhuo, J.; Mendelsohn, F. A., Localization and function of angiotensin AT1 receptors. Am. J. Hypertens., 2000, 13(1 Pt 2), 31S-38S.
119. Zhou, Ming-Sheng; Schulman, Ivonne H; Zeng, Qiang, Link between the renin-angiotensin system and insulin resistance: Implications for cardiovascular disease. Vasc. Med., 2012, 1-12.
120. Touyz, R. M.; Endemann, D.; He, G.; Li, J. S.; Schiffrin, E. L. Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR. Hypertension, 1999, 33(1 Pt 2), 366-372.
121. Costa, M. A.; Lopez Verrilli, M. A.; Gomez, K. A.; Nakagawa, P.; Pena, C.; Arranz, C.; Gironacci, M. M. Angiotensin-(1-7) upregulates cardiac nitric oxide synthase in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol., 2010, 299(4), H1205-H1211.
122. Rigat, B.; Hubert, C.; Alhenc-Gelas, F.; Cambien, F.; Corvol, P.; Soubrier, F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest., 1990, 86(4), 1343-1346.
123. Almeida, J. A.; Boullosa, D. A.; Pardono, E.; Lima, R. M.; Morais, P. K.; Denadai, B. S.; Souza, V. C.; Nobrega, O. T.; Campbell, C. S.; Simoes, H. G. The influence of ACE genotype on cardiovascular fitness of moderately active young men. Arq Bras Cardiol., 2012, 98(4), 315-320.
124. Defoor, J.; Vanhees, L.; Martens, K.; Matthijs, G.; Van Vlerken, A.; Zielinska, D.; Schepers, D.; Vlietinck, R.; Fagard, R. The CAREGENE study: ACE gene I/D polymorphism and effect of physical training on aerobic power in coronary artery disease. Heart, 2006, 92(4), 527-528.
125. Santana, H. A.; Moreira, S. R.; Neto, W. B.; Silva, C. B.; Sales, M. M.; Oliveira, V. N.; Asano, R. Y.; Espindola, F. S.; Nobrega, O. T.; Campbell, C. S.; Simoes, H. G. The higher exercise intensity and the presence of allele I of ACE gene elicit a higher post-exercise blood pressure reduction and nitric oxide release in elderly women: an experimental study. BMC Cardiovasc. Disord., 2011, 11, 71.
126. Gavras, I. Bradykinin-mediated effects of ACE inhibition. Kidney Int., 1992, 42(4), 1020-1029.
127. Barretti, D. L.; Magalhaes Fde, C.; Fernandes, T.; do Carmo, E. C.; Rosa, K. T.; Irigoyen, M. C.; Negrao, C. E.; Oliveira, E. M., Effects of aerobic exercise training on cardiac Renin-Angiotensin system in an obese zucker rat strain. PLoS One, 2012, 7(10), e46114.
128. Carroll, J. F.; Kyser, C. K. Exercise training in obesity lowers blood pressure independent of weight change. Med. Sci. Sports Exerc., 2002, 34(4), 596-601.
129. Berggren, J. R.; Boyle, K. E.; Chapman, W. H.; Houmard, J. A. Skeletal muscle lipid oxidation and obesity: influence of weight loss and exercise. Am. J. Physiol. Endocrinol. Metab., 2008, 294(4), E726-E732.
130. Pereira, M. G.; Ferreira, J. C.; Bueno, C. R., Jr.; Mattos, K. C.; Rosa, K. T.; Irigoyen, M. C.; Oliveira, E. M.; Krieger, J. E.; Brum, P. C. Exercise training reduces cardiac angiotensin II levels and prevents cardiac dysfunction in a genetic model of sympathetic hyperactivity-induced heart failure in mice. Eur. J. Appl. Physiol., 2009, 105(6), 843-850.
131. Lee, J.; Cho, H. S.; Park, S.; Kim, W. K. Regular exercise produced cardioprotective effects on rat's heart with hypertension induced by L-NAME administration. Clin. Exp. Hypertens., 2009, 31(4), 364-375.
132. Fernandes, T.; Hashimoto, N. Y.; Magalhaes, F. C.; Fernandes, F. B.; Casarini, D. E.; Carmona, A. K.; Krieger, J. E.; Phillips, M. I.; Oliveira, E. M. Aerobic exercise training-induced left ventricular hypertrophy involves regulatory MicroRNAs, decreased angiotensin-converting enzyme-angiotensin ii, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin (1-7). Hypertension, 2011, 58(2), 182-189.
133. Kar, S.; Gao, L.; Zucker, I. H. Exercise training normalizes ACE and ACE2 in the brain of rabbits with pacing-induced heart failure. J. Appl. Physiol., 2010, 108(4), 923-932.
134. Filho, A. G.; Ferreira, A. J.; Santos, S. H.; Neves, S. R.; Silva Camargos, E. R.; Becker, L. K.; Belchior, H. A.; Dias-Peixoto, M. F.; Pinheiro, S. V.; Santos, R. A. Selective increase of angiotensin(1-7) and its receptor in hearts of spontaneously hypertensive rats subjected to physical training. Exp. Physiol., 2008, 93(5), 589-598.
135. Prada, F.J.A.; Voltarelli, F.A.; Oliveira, C.A.M.; Gobatto, C.A.; Macedo, D.V.; Mello, M.A.R. Aerobic condition and oxidative stress in rats swim-trained at the anaerobic threshold intensity. R. Bras. Ci. Mov., 2004, 12(27), 29-34.
136. Silva, O. N.; Mulder, K. C.; Barbosa, A. E.; Otero-Gonzalez, A. J.; Lopez-Abarrategui, C.; Rezende, T. M.; Dias, S. C.; Franco, O. L. Exploring the pharmacological potential of promiscuous hostdefense peptides: from natural screenings to biotechnological applications. Front Microbiol., 2011, 2, 232.
137. Rodrigues-Ferreira, S.; Abdelkarim, M.; Dillenburg-Pilla, P.; Luissint, A. C.; di-Tommaso, A.; Deshayes, F.; Pontes, C. L.; Molina, A.; Cagnard, N.; Letourneur, F.; Morel, M.; Reis, R. I.; Casarini, D. E.; Terris, B.; Couraud, P. O.; Costa-Neto, C. M.; Di Benedetto, M.; Nahmias, C. Angiotensin II facilitates breast cancer cell migration and metastasis. PLoS One, 2012, 7(4), e35667.
138. Cochaud, S.; Chevrier, L.; Meunier, A. C.; Brillet, T.; Chadeneau, C.; Muller, J. M. The vasoactive intestinal peptide-receptor system is involved in human glioblastoma cell migration. Neuropeptides, 2010, 44(5), 373-383.
139. Desrues, L.; Lefebvre, T.; Lecointre, C.; Schouft, M. T.; Leprince, J.; Compere, V.; Morin, F.; Proust, F.; Gandolfo, P.; Tonon, M. C.; Castel, H. Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity. PLoS One, 2012, 7(5), e36319.
140. Watanabe, T.; Pakala, R.; Katagiri, T.; Benedict, C. R., Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation, 2001, 104(1), 16-18.
141. Shi, L.; Ding, W.; Li, D.; Wang, Z.; Jiang, H.; Zhang, J.; Tang, C. Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis, 2006, 188(2), 260-264.
142. Guidolin, D.; Albertin, G.; Oselladore, B.; Sorato, E.; Rebuffat, P.; Mascarin, A.; Ribatti, D. The pro-angiogenic activity of urotensin-II on human vascular endothelial cells involves ERK1/2 and PI3K signaling pathways. Regul. Pept., 2010, 162(1-3), 26-32.
143. Johns, D. G.; Ao, Z.; Naselsky, D.; Herold, C. L.; Maniscalco, K.; Sarov-Blat, L.; Steplewski, K.; Aiyar, N.; Douglas, S. A. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn. Schmiedebergs Arch. Pharmacol., 2004, 370(4), 238-250.
144. Coulouarn, Y.; Lihrmann, I.; Jegou, S.; Anouar, Y.; Tostivint, H.; Beauvillain, J. C.; Conlon, J. M.; Bern, H. A.; Vaudry, H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc. Natl. Acad. Sci. USA, 1998, 95(26), 15803-15808.
145. You, Z.; Genest, J., Jr.; Barrette, P. O.; Hafiane, A.; Behm, D. J.; D'Orleans-Juste, P.; Schwertani, A. G. Genetic and pharmacological manipulation of urotensin II ameliorate the metabolic and atherosclerosis sequalae in mice. Arterioscler Thromb. Vasc. Biol., 2012, 32(8), 1809-1816.
146. Knochel, C.; Oertel-Knochel, V.; O'Dwyer, L.; Prvulovic, D.; Alves, G.; Kollmann, B.; Hampel, H. Cognitive and behavioural effects of physical exercise in psychiatric patients. Prog. Neurobiol., 2012, 96(1), 46-68.
147. Linz, W.; Wiemer, G.; Schaper, J.; Zimmermann, R.; Nagasawa, K.; Gohlke, P.; Unger, T.; Scholkens, B. A. Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Mol. Cell Biochem., 1995, 147(1-2), 89-97.
148. Bonner, G. Diagnosis of arterial hypertension. Acta. Med. Austriaca., 1995, 22(3), 32-34.
149. Barreto, S. A.; Chaguri, L. C.; Prezoto, B. C.; Lebrun, I. Characterization of two vasoactive peptides isolated from the plasma of the snake Crotalus durissus terrificus. Biomed. Pharmacother., 2012, 66(4), 256-265.
150. Wenzel, D.; Koch, M.; Matthey, M.; Heinemann, J. C.; Fleischmann, B. K. Identification of a novel vasoconstrictor peptide specific for the systemic circulation. Hypertension, 2012, 59(6), 1256-1262.
151. Zhang, W.; Shibamoto, T.; Kuda, Y.; Shinomiya, S.; Kurata, Y. The responses of the hepatic and splanchnic vascular beds to vasopressin in rats. Biomed. Res., 2012, 33(2), 83-88.